# Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct05475678/  
OnCo record `nct05475678` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Zhenzhen Liu, now recruiting.

## Summary

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT05475678 by Zhenzhen Liu, with a registry enrolment figure of 369 participants, started 2022-12-20 and due to reach its primary completion in 2025-05-31. Interventions recorded: （Carrelizumab + TCb） regimen; TCb regimen. Conditions listed: Breast Cancer; Triple Negative Breast Cancer; Camrelizumab. Triple-negative eligibility wording from the registry: "Pathologically proven triple negative breast cancer:". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05475678
- Phase: 2
- Setting: A Randomized, Open Label, Parallel Controlled, Multicenter Phase II Clinical Study of Carelizumab Combined With TCb (Docetaxel+Carboplatin) Versus TCb Neoadjuvant Therapy for Triple Negative Breast Cancer
- Sponsor: Zhenzhen Liu
- Enrolled: 369

## Sources

- ClinicalTrials.gov NCT05475678: https://clinicaltrials.gov/study/NCT05475678

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05475678.json